Report Phase 3 flu vaccine (mRNA-1010) southern hemisphere immunogenicity data
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Nov 2022
- Due
- 31 Mar 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the southern hemisphere immunogenicity study of mRNA-1010 is fully enrolled with approximately 6,000 adult participants, and the data readout is expected in the first quarter of 2023”
What we found
Evidence strength A What the grades mean
A May 2023 8-K states interim results from the Southern Hemisphere P301 study were announced in February 2023, before the Q1 2023 deadline.
-
A Moderna 8-K filed 2023-05-04
“A Phase 3 trial (P301) was conducted in the Southern Hemisphere to evaluate safety and non-inferior immunogenicity compared to a licensed flu vaccine; interim results from that study were previously announced in February.” ✓ confirmed on the page
-
A Moderna 10-Q filed 2023-05-04
“The first Phase 3 trial (P301) of mRNA-1010 was conducted in the Southern Hemisphere to evaluate safety and non-inferior immunogenicity compared to a licensed flu vaccine.” ✓ confirmed on the page
Market reaction: the shares moved +0.1% against the S&P 500 over the three sessions around the disclosure (3 May 2023 to 8 May 2023). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Southern hemisphere immunogenicity data for mRNA-1010 flu vaccine
- Target
- 6,000 adult participants
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-MRNA-006190 · Corrections policy